Effect of sacubactril valsartan sodium tablets on patients with heart failure
Objective To explore the effect of sacubactril valsartan sodium tablets(trade name:Entresto)on patients with heart failure.Methods A total of 96 patients with heart failure were selected as research subjects and randomly divided into a control group and an observation group,with 48 cases in each group.The control group was treated with enalapril maleate tablets,and the observation group was treated with sacubactril valsartan sodium tablets.Comparison was made on therapeutic effects,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)],renal function indicators[blood urea nitrogen(BUN),serum creatinine(SCr)and estimated glomerular filtration rate(eGFR)],serum markers[brain natriuretic peptide(BNP),cardiac troponin I(cTnI)and hypersensitive C-reactive protein(hs-CRP)].Results The total effective rate of 93.75%in the observation group was higher than 77.08%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in LVEF,LVEDD and LVESD between the two groups(P>0.05).After treatment,LVEF of(43.19±3.13)%in the observation group was significantly higher than(36.64±3.82)%in the control group;and LVEDD of(52.15±2.54)mm and LVESD of(42.31±0.32)mm were significantly smaller than(57.71±2.94)and(46.42±0.51)mm in the control group.The difference was statistically significant(P<0.05).Before treatment,there was no significant difference in BUN,SCr and eGFR levels between the two groups(P>0.05).After treatment,BUN of(6.40±1.53)mmol/L and SCr of(75.40±18.44)μmol/L in the observation group were significantly lower than(7.17±1.35)mmol/L and(86.51±14.95)μmol/L in the control group;and eGFR of(88.31±14.32)ml/(min·1.73 m2)was significantly higher than(81.42±15.98)ml/(min·1.73 m2)in the control group.The difference was statistically significant(P<0.05).Before treatment,there was no significant difference in BNP,cTnI and hs-CRP levels between the two groups(P>0.05).After treatment,the observation group had BNP of(522.41±48.37)ng/L,cTnI of(0.30±0.07)μg/L and hs-CRP of(16.24±10.14)mg/L,which were significantly lower than(689.45±50.25)ng/L,cTnI(0.40±0.08)μg/L and hs-CRP(28.19±10.27)mg/L in the control group.The difference was statistically significant(P<0.05).Conclusion The effect of sacubactril valsartan sodium tablets in the treatment of patients with heart failure is definite,which helps to promote the recovery of patients'heart and kidney function,reduce the level of myocardial damage and inflammation,and is worthy of popularization and application.
Heart failureSacubactril valsartan sodium tabletsCardiac function indicators
万方数据
维普
